A post-hoc analysis of the EMPA-REG OUTCOME trial showed that empagliflozin may reduce risk of the post-acute HF rehospitalization and mortality, which provide a cogent rationale for SGLT2 inhibitors in patients hospitalized with decompensated HF (129). This evidence concerns the gene SLC5A2 and hydrops fetalis.